Rachel Fearns

TL;DR: These results show the first substantive post-exposure protection by a small-molecule antiviral compound against EBOV in nonhuman primates, and the broad-spectrum antiviral activity of GS-5734 in vitro against other pathogenic RNA viruses, including filoviruses, arenavirus, and coronavirus suggests the potential for wider medical use.

TL;DR: Although M2-1 was found to have profound effects on transcription, it had no effect on replication of any minigenome tested, suggesting that it is not an active participant in RNA replication or regulation of RNA replication.

TL;DR: RSV is notable for a historic vaccine failure in the 1960s involving a formalin-inactivated vaccine that primed for enhanced disease in RSV naïve recipients and development of subunit or other protein-based vaccines for pediatric use is hampered by the possibility of enhanced disease and the difficulty of reliably demonstrating its absence in preclinical studies.

TL;DR: N4-hydroxycytidine (NHC) is identified as a potent inhibitor of RSV, influenza B viruses, and IAVs of human, avian, and swine origins and is a promising candidate for future clinical development as a treatment option for influenza-like diseases.

TL;DR: There was no evidence of a significant switch in positive-sense RNA synthesis from transcription (synthesis of mRNAs) to RNA replication (syndhesis of antigenome), and the synthesis ofpositive-sense antigenome and mRNA appeared to occur at a fixed ratio, with mRNA being by far the more abundant product.